Lupus

The latest clinical trials and emerging therapies are reviewed in this informative guide to this disease of the immune system, along with specific topics addressing prevention, exercise, and diet, enhanced with a glossary of terms, appendix of related resource materials, and more.

This completely updated and expanded 2nd edition of Systemic Lupus Erythematosus, A Manual includes topics not covered previously with contributors who are at the forefront of each specific topic and with a global appeal. Each chapter is short and is presented critically with selected references, which should be valuable to a wider audience. This book combines basic with clinical science to help internists and specialists in the diagnosis and management of patients with SLE. It is a quick referral for people in the pharmaceutical industry in their efforts to bring much-needed drugs. It provides all the needed information to basic researchers old and new alike, who wish to enter the field of lupus and systemic autoimmunity in general. Focused state-of-the-art chapters prepared by top-notch experts in the field Latest understanding of cellular, molecular, biochemical aspects of disease pathogenesis Advanced aspects of genetic, microbiome, environmental, hormonal, and immunological contribution to the expression of the disease Current understanding of clinical features of the disease Recent efforts to develop new treatments

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness. To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries. Completely updated, revised, and expanded with the most comprehensive and accessible reference on SLE for clinicians and scientists Full-color presentation throughout the book Provides the latest information available on diagnosis and treatment Incorporates an international panel of authors who are experts in their fields, with an emphasis on young, cutting-edge scientists and physicians

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that manifests with a myriad of clinical and laboratory features. The assessment of SLE is comprehensive and includes different core set domains; disease activity, damage, health-related quality of life, adverse events and economic impact. This comprehensive book is focused on the instruments and outcome measures utilized in the assessment of SLE. It targets different audiences including physicians, scientists/researchers and different health professionals interested in learning about the art of measurement in SLE. The book highlights the importance of measurement in the assessment of SLE in a clinical settings, research and clinical trials. Each of the chapters provide a systematic approach to the instruments utilized in the assessment of a specific construct in SLE (e.g., disease activity, fatigue, etc.) and incorporate a comprehensive coverage of disease specific and disease generic measures. It also discusses different patient-reported outcomes that are crucial to reflect patient perceptions of their health condition and cover constructs such as fatigue, pain, anxiety and depression, cognition, frailty, and many others.

Now completely updated! The best-selling, most comprehensive guide to lupus, its complications, and management. Lupus is an autoimmune disease that can attack any body organ. It is three times more common in the United States today than it was in the 1980s, so there is an increased need for accurate, practical information on this potentially devastating disease. Lupus expert and clinician Donald E. Thomas, Jr., MD, provides all the helpful information patients need so they can understand and treat this disease. Highlighting amazing advancements in the diagnosis and treatment of lupus, this edition includes new and expanded information on: • The latest FDA-approved medications • How lupus affects different body parts • Advanced labs that improve lupus diagnosis and treatment • The role of the microbiome and anti-inflammatory diets • Updated recommendations for those who are pregnant or breastfeeding • Childhood-onset lupus • The interaction between COVID-19 and lupus • Non-drug treatments, complementary medicine, and medical cannabis The gold standard since it was first published and carefully reviewed by experts in the field, the latest edition of The Lupus Encyclopedia is essential for patients, health care providers, and families. Bonus content on insurance issues and information about working with lupus and disability is also available online. Endorsed by The Lupus Foundation of America Contributors: Jemima Albayda, MD; Divya Angra, MD; Alan N. Baer, MD; Sasha Bernatsky, MD, PhD; George Bertsias, MD, PhD; Ashira D. Blazer, MD; Ian Bruce, MD; Jill Buyon, MD; Yashaar Chaichian, MD; Maria Chou, MD; Sharon Christie, Esq; Angelique N. Collamer, MD; Ashté Collins, MD; Caitlin O. Cruz, MD; Mark M. Cruz, MD; Dana DiRenzo, MD; Jess D. Edison, MD; Titilola Falasinnu, PhD; Andrea Fava, MD; Cheri Frey, MD; Neda F. Gould, PhD; Nishant Gupta, MD; Sarthak Gupta, MD; Sarfaraz Hasni, MD; David Hunt, MD; Mariana J. Kaplan, MD; Alfred Kim, MD; Deborah Lyu Kim, DO; Rukmini Konatalapalli, MD; Fotios Koumpouras, MD; Vasileios C. Kyttaris, MD; Jerik Leung, MPH; Hector A. Medina, MD; Timothy Niewold, MD; Julie Nusbaum, MD; Ginette Okoye, MD; Sarah L. Patterson, MD; Ziv Paz, MD; Darryn Potosky, MD; Rachel C. Robbins, MD; Neha S. Shah, MD; Matthew A. Sherman, MD; Yevgeniy Sheyn, MD; Julia F. Simard, ScD; Jonathan Solomon, MD; Rodger Stitt, MD; George Stojan, MD; Sangeeta Sule, MD; Barbara Taylor, CPPM, CRHC; George Tsokos, MD; Ian Ward, MD; Emma Weeding, MD; Arthur Weinstein, MD; Sean A. Whelton, MD

For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the updated 9th Edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes. Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education. Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients. Offers an increased focus on the clinical management of related disorders such as Sjogren’s syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS). Presents the knowledge and expertise of more international contributors to provide new global perspectives on manifestations, diagnosis, and treatment. Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, and more schematic diagrams throughout.

The scope of this contributed volume is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical literature. This book will critically appraise the current understanding of important immunological pathways that contribute to the pathogenesis of lupus. We will review the role of interferons as part of the innate immune defects that perpetuate the loss of self-tolerance in SLE. B cell hyperactivity, as a defining hallmark of SLE, and different strategies of B cell targeted therapy will be discussed. The role of co-stimulation or immune checkpoint molecules in activating B and T cells will be reviewed, as well as other cytokines that serve in the amplification loop promoting a more proinflammatory Th1 or Th17 responses. Intracellular targets, such as signaling molecules in the JAK/STAT pathway, or a variety of kinases and proteasomes, can cause a cascading downstream effect of transcriptional responses that are important in SLE. Immune homeostasis can also be restored by bolstering the naturally occurring anti-inflammatory mechanisms. Glucocorticoid, as a potent natural anti-inflammatory hormone, can mediate its effects by recruiting histone deacetylase that serve to repress gene transcription. Glucocorticoid-induced leucine zipper is a gene upregulated by glucocorticoid that can be a potential target for development of anti-inflammatory strategy. Finally, T regulatory cells can be utilized to help restore to immune tolerance and are amongst the latest focus of therapeutic development in SLE.

Looking for a better way to manage life with a chronic illness? Despite Lupus will guide you through the proven steps needed to obtain the emotional and physical wellness you deserve.